Myasthenia Gravis Inebilizumab Trial (MINT): Efficacy, Pharmacodynamics, and Immunogenicity in AChR+ Cohort (Week 52) (S14.009)

Kristen Clarkson; Kimiaki Utsugisawa; Michael Benatar; Emma Ciafaloni; Maria Leite; John Vissing; Fengming Tang; Cody J. Peer; Sue Cheng; James Howard; Richard Nowak

doi:10.1212/wnl.0000000000216387

June 9, 2026Neurology

Myasthenia Gravis Inebilizumab Trial (MINT): Efficacy, Pharmacodynamics, and Immunogenicity in AChR+ Cohort (Week 52) (S14.009)

View at Publisher

Ask AI

Bookmark

Share

Key Points

This trial aims to assess the effectiveness and immune response of inebilizumab in treating generalized Myasthenia Gravis.
Evaluated efficacy, pharmacodynamics, and immunogenicity of inebilizumab in AChR+ individuals.
Focused on the week 52 outcomes in the inebilizumab treatment group.
Inebilizumab significantly improved muscle strength in AChR+ subjects, with clear pharmacodynamic effects.
Demonstrated favorable immunogenicity profile, indicating a low incidence of adverse immune responses.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

To evaluate the efficacy, pharmacodynamics, and immunogenicity of inebilizumab, a monoclonal antibody targeting CD19+ B-cells, in acetylcholine receptor antibody-positive (AChR+) generalized Myasthenia Gravis (gMG).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Clarkson et al. (2026) studied this question.

synapsesocial.com/papers/6a2cf3d6faef96ed7f0564d1 https://doi.org/10.1212/wnl.0000000000216387

View at Publisher

Ask AI

Bookmark

Share

Myasthenia Gravis Inebilizumab Trial (MINT): Efficacy, Pharmacodynamics, and Immunogenicity in AChR+ Cohort (Week 52) (S14.009)

Key Points

Ask about this paper

Abstract

Discussion

Cite This Study

Myasthenia Gravis Inebilizumab Trial (MINT): Efficacy, Pharmacodynamics, and Immunogenicity in AChR+ Cohort (Week 52) (S14.009)

Key Points

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading